Narrative review on unspecified topic lacks reported population or outcomes

Photo by Brett Jordan / Unsplash

Frontiers in Medicine Published May 8, 2026 Medically reviewed May 8, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that this narrative review lacks specific population or outcome data.

The provided source is identified as a narrative review. The publication type is explicitly listed as a review. No specific conditions, medications, or population are reported in the input data. The study phase is not reported, and the setting remains undefined. No sample size or follow-up duration is available for this source.

Key findings or arguments are not reported in the input JSON. The main results section is empty, meaning no pooled effect sizes or qualitative conclusions are present. Safety data, including adverse events and tolerability, are not reported. Serious adverse events and discontinuations are also absent from the data.

Limitations are not reported by the authors. Funding or conflicts of interest are not reported. Practice relevance is not reported. Because the input lacks specific details, no causal language or definitive clinical guidance can be offered. The evidence certainty is not reported, and the study design does not support strong conclusions.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Interferon-induced transmembrane proteins (IFITMs) are small, non-enzymatic factors that reshape host cell membranes to block pathogen entry. In this review, we bring together what is known about their genetics and evolution, how their structure relates to function, and how they are regulated after translation. A central theme is how the amphipathic helix organizes lipids and bends membranes to stop fusion pores from forming. We connect well-studied antiviral cases, influenza A, HIV-1, flaviviruses, and the context-dependent effects seen with coronaviruses, to newer cell-biology insights, including cooperation with ZMPSTE24 and dependence on phosphoinositides. Beyond viruses, IFITMs appear to control how extracellular vesicles deliver cargo, acting as broader “membrane gatekeepers” of cell-to-cell communication. Placing IFITMs in the host–pathogen arms race, we outline how viruses evade IFITM activity or dampen its induction, while helminth and protozoan parasites rewire interferon pathways more broadly; their secreted miRNAs and proteases commonly suppress NF-κB and may intersect with IFITM-regulated uptake. Finally, we survey noncanonical roles in development, immunity, and cancer, and highlight open questions about topology, lipid dynamics, and targeting specificity. Together, these threads present IFITMs as adaptable effectors linking innate immunity, membrane biophysics, and disease, with clear implications for antivirals, immuno-oncology, and vesicle-based therapies.